Karus Therapeutics: Developing best-in-class medicines to treat cancer




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Karus Therapeutics: Developing best-in-class medicines to treat cancer
Released on: January 27, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Karus is a leader in the design and development of innovative cancer therapies; these small-molecule drugs combine targeted therapy with immunotherapeutic activity for the effective treatment of a diverse range of tumors.
  • Summary
  • Participants
  • Company
Karus is a leader in the design and development of innovative cancer therapies; these small-molecule drugs combine targeted therapy with immunotherapeutic activity for the effective treatment of a diverse range of tumors. Our approach has broad potential application in the treatment of hematological cancers and solid tumors.
Simon is a business professional with two decades’ experience of creating and developing innovative life science companies. Before he joined Karus as the Company's CEO in 2006, he was Director of Business Development at Ablynx NV (Ghent, Belgium), where he secured a number of research, development and licensing agreements with major pharmaceutical companies including Wyeth (now Pfizer) and Novartis. During this time, he played a key role in Ablynx's growth from early-stage to one of Europe's most promising antibody companies. Prior to Ablynx, Simon was Director of Business Development at Active Biotech AB (Lund, Sweden), where he spun-out the molecular evolution company, Isogenica Ltd (Cambridge, UK), later joining the spin-out as Vice President of Business Development. Simon has held other key commercial appointments at Actinova Ltd (Cambridge, UK), and Actigen Ltd (Cambridge, UK). He has also occupied senior commercial roles at the Health Protection Agency (Salisbury, UK) and within the Jasmin group of companies. Simon has a degree in Medicinal Chemistry, a Life Science PhD and an executive MBA from Loughborough University Business School. Simon is on the Advisory Board of MedCity (http://www.medcitylondon.com/), an initiative that positions London and South-East England as a world leading, interconnected region for life science research, development, manufacturing and commercialisation. Simon is also a co-founder of Angels4LifeSciences (http://www.a4ls.com), an angel investment community committed to early-stage UK-based life science companies.
Karus Therapeutics
The Company, led by a highly experienced management team, has a track record of scientific excellence in small molecule drug discovery. This has produced therapeutic programmes with the potential to be either first- or best-in-class agents for the treatment of inflammatory disease and cancer. These innovative programmes are underpinned by a broad intellectual property portfolio. Karus operates an outsourced business model: retaining drug design, experimental chemistry and in vitro biology research in-house, whilst outsourcing a significant proportion of its R&D activities to a network of internationally-recognised CROs. This approach has allowed Karus to remain capital efficient and flexible whilst advancing multiple R&D programmes through key value inflection points. Karus Therapeutics has a history of strong financial management and is backed by some of the biotech industry’s most experienced investors. By focusing its financial resources on creating value in its therapeutic programmes, the company has developed a strong track-record of delivering key R&D goals on time and to budget.